Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

Affiliations

¹ University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Birmingham, AL, USA.
² University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, AL, USA.
³ Southern Research Institute, Department of Oncology, Birmingham, AL, USA.
⁴ University of Alabama at Birmingham, Department of Pathology, Division of Molecular & Cellular Pathology, Birmingham, AL, USA.
⁵ Ohio State University, Department of Medicinal Chemistry and Pharmacognosy, Columbus, OH, USA.
⁶ University of Virginia, Department of Oncology, Division of Gynecologic Oncology, Charlottesville, VA, USA.
⁷ University of Alabama at Birmingham, Department of Epidemiology, Birmingham, AL, USA.
⁸ University of Alabama at Birmingham, Department of Medicine, Division of Hematology & Oncology, Birmingham, AL, USA.

Published Erratum

Rebecca C Arend et al. Oncotarget. 2018.

. 2018 Apr 10;9(27):19459.

doi: 10.18632/oncotarget.25151.

¹ University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Birmingham, AL, USA.
² University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, AL, USA.
³ Southern Research Institute, Department of Oncology, Birmingham, AL, USA.
⁴ University of Alabama at Birmingham, Department of Pathology, Division of Molecular & Cellular Pathology, Birmingham, AL, USA.
⁵ Ohio State University, Department of Medicinal Chemistry and Pharmacognosy, Columbus, OH, USA.
⁶ University of Virginia, Department of Oncology, Division of Gynecologic Oncology, Charlottesville, VA, USA.
⁷ University of Alabama at Birmingham, Department of Epidemiology, Birmingham, AL, USA.
⁸ University of Alabama at Birmingham, Department of Medicine, Division of Hematology & Oncology, Birmingham, AL, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.13466.].

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Arend RC, et al. Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Oncotarget. 2016. PMID: 27888804 Free PMC article.